LuCE aims to raise awareness about inequities regarding the access to lung cancer treatment and care in Europe. Moreover, it advocates European policies that will lead to improvements in lung cancer prevention, early detection, treatment and care.
Lung Cancer Europe provides a European platform for national lung cancer patient advocacy groups and supports the establishment of those groups in countries where such groups do not yet exist. Our member organisations and associate members come from all over Europe.
Lung cancer is literally the biggest cancer killer worldwide – causing more deaths than breast and prostate cancer put together all over the world. Read more about our diagnosis, types and stages of lung cancer, treatments and clinical trials, but also how to cope with lung cancer.
We invite all interested ESMO members to visit us @LuCE booth located in the society village at ESMO 2018 in Munich. Name: LuCE Hall: B1 Stand: PA 8 LuCE team will answer your questions and will provide materials and information about #lungcancer. Check out the map 1 and map 2 to easily find us.
According to tthe new statistics, in both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6 % of the total cases) and the leading cause of cancer death (18.4 % of the total cancer deaths), closely followed by female breast cancer (11.6 %), prostate cancer (7.1 %), and colorectal cancer (6.1 %) for incidence and colorectal cancer (9.2 […]
During the congress, one of the topics covered focused on the importance of EGFR TKIs in Advanced NSCLC. Apply expert recommendations for frontline therapy for advanced EGFR-mutated NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors Compare the efficacy and safety of first-generation EGFR TKIs with later-generation EGFR TKIs Examine current recommendations for molecular […]
During the World Congress on Lung Cancer held this year in Toronto, Canada were presented the findings of NELSON study. These demonstrate that the use of computed tomography (CT) screening among asymptomatic men at high risk for lung cancer led to a 26 percent (9-41%, 95% CI) reduction in lung cancer deaths at 10 years of study follow-up (at 86% […]
